Efficacy and safety of probiotics in eradicating Helicobacter pylori: A network meta-analysis.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
entrez:
16
4
2019
pubmed:
16
4
2019
medline:
23
4
2019
Statut:
ppublish
Résumé
Due to decreasing eradication rate and increasing side effects, probiotics have gradually become an important supplement to standard eradication regimens for Helicobacter pylori. To evaluate the effectiveness and safety of probiotics in facilitating the eradication of H pylori and to explore the best timing and duration of probiotic supplementation, use of eradication regimens, strains, locations, and common side effects. Eligible studies were retrieved from the PubMed, EMBASE, Cochrane Library, Web of Science, and CNKI databases, and we applied the Stata 12.0 software for the standard meta-analysis and network meta-analysis. Forty eligible studies with 8924 patients were included in the analysis. We used a random-effects model (I = 52.1% and I = 81.4%) to analyze the eradication rate and the incidence of total side effects by intention to treat (ITT). Compared with the control group, a higher eradication rate (relative risk [RR] 1.140, 95% confidence interval (CI) 1.101-1.180, P < .001) and lower incidence of total side effects (RR 0.470, 95% CI 0.391-0.565, P < .001) were observed in the probiotic group. In the subgroup analysis, we evaluated the surface under the cumulative ranking curve scores for the before + same (75.2%), >2 weeks (92.6%), probiotic + quadruple regimen (99.9%), Lactobacillus (73.6%), multiple strains (72.1%), China (98.5%) groups. The rankings of common side effects are shown in Table 6. SUCRA scores for diarrhea (39.7%), abdominal pain (43.9%), nausea (78.8%), taste disturbance (99.6%), vomiting (7.1%), and constipation (30.9%) were reported. The consistency of all comparison groups was good. Probiotics improved the eradication rate and reduced side effects when added to the treatments designed to eradicate H pylori. The use of probiotics before the eradication treatment and throughout the eradication treatment, and also the use of probiotics for more than 2 weeks, exerted better eradication effects. Probiotics combined with the bismuth quadruple regimen was the best combination. Lactobacillus and multiple strains were better choices of probiotic strains. The eradication effect observed in China was better than the effect observed in other countries.
Sections du résumé
BACKGROUND
BACKGROUND
Due to decreasing eradication rate and increasing side effects, probiotics have gradually become an important supplement to standard eradication regimens for Helicobacter pylori.
OBJECTIVE
OBJECTIVE
To evaluate the effectiveness and safety of probiotics in facilitating the eradication of H pylori and to explore the best timing and duration of probiotic supplementation, use of eradication regimens, strains, locations, and common side effects.
METHODS
METHODS
Eligible studies were retrieved from the PubMed, EMBASE, Cochrane Library, Web of Science, and CNKI databases, and we applied the Stata 12.0 software for the standard meta-analysis and network meta-analysis.
RESULTS
RESULTS
Forty eligible studies with 8924 patients were included in the analysis. We used a random-effects model (I = 52.1% and I = 81.4%) to analyze the eradication rate and the incidence of total side effects by intention to treat (ITT). Compared with the control group, a higher eradication rate (relative risk [RR] 1.140, 95% confidence interval (CI) 1.101-1.180, P < .001) and lower incidence of total side effects (RR 0.470, 95% CI 0.391-0.565, P < .001) were observed in the probiotic group. In the subgroup analysis, we evaluated the surface under the cumulative ranking curve scores for the before + same (75.2%), >2 weeks (92.6%), probiotic + quadruple regimen (99.9%), Lactobacillus (73.6%), multiple strains (72.1%), China (98.5%) groups. The rankings of common side effects are shown in Table 6. SUCRA scores for diarrhea (39.7%), abdominal pain (43.9%), nausea (78.8%), taste disturbance (99.6%), vomiting (7.1%), and constipation (30.9%) were reported. The consistency of all comparison groups was good.
CONCLUSIONS
CONCLUSIONS
Probiotics improved the eradication rate and reduced side effects when added to the treatments designed to eradicate H pylori. The use of probiotics before the eradication treatment and throughout the eradication treatment, and also the use of probiotics for more than 2 weeks, exerted better eradication effects. Probiotics combined with the bismuth quadruple regimen was the best combination. Lactobacillus and multiple strains were better choices of probiotic strains. The eradication effect observed in China was better than the effect observed in other countries.
Identifiants
pubmed: 30985706
doi: 10.1097/MD.0000000000015180
pii: 00005792-201904120-00067
pmc: PMC6485819
doi:
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15180Références
JAMA. 2018 Aug 07;320(5):499-500
pubmed: 30027207
Helicobacter. 2013 Aug;18(4):280-4
pubmed: 23433200
Zhonghua Yi Xue Za Zhi. 2017 Aug 8;97(30):2353-2356
pubmed: 28822453
Helicobacter. 2008 Aug;13(4):261-8
pubmed: 18665934
Am J Gastroenterol. 2007 May;102(5):951-6
pubmed: 17313499
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
Eur J Clin Microbiol Infect Dis. 2011 Apr;30(4):555-9
pubmed: 21207091
World J Gastroenterol. 2015 Apr 14;21(14):4345-57
pubmed: 25892886
Aliment Pharmacol Ther. 2010 Nov;32(9):1069-79
pubmed: 21039671
Int J Clin Exp Med. 2015 Apr 15;8(4):6530-43
pubmed: 26131283
Gastroenterology. 2017 Jun;152(8):1889-1900.e9
pubmed: 28192108
World J Gastroenterol. 2018 Jan 7;24(1):139-149
pubmed: 29358890
Am J Gastroenterol. 2017 Feb;112(2):212-239
pubmed: 28071659
FEMS Immunol Med Microbiol. 2002 Jan 14;32(2):105-10
pubmed: 11821231
FEMS Microbiol Lett. 2017 Jun 15;364(11):
pubmed: 28505287
Hepatogastroenterology. 2011 Jul-Aug;58(109):1148-52
pubmed: 21937367
World J Gastroenterol. 2014 Dec 21;20(47):18013-21
pubmed: 25548501
JAMA. 2017 Apr 11;317(14):1400-1402
pubmed: 28399250
Control Clin Trials. 1996 Feb;17(1):1-12
pubmed: 8721797
World J Gastroenterol. 2012 Nov 21;18(43):6302-7
pubmed: 23180952
Aliment Pharmacol Ther. 2002 Sep;16(9):1669-75
pubmed: 12197847
J Epidemiol Community Health. 1998 Jun;52(6):377-84
pubmed: 9764259
Gastroenterol Hepatol. 2016 Dec;39(10):697-721
pubmed: 27342080
Sci Rep. 2016 Aug 30;6:32334
pubmed: 27573193
Helicobacter. 2010 Jun;15(3):206-13
pubmed: 20557362
BMC Gastroenterol. 2013 Mar 26;13:56
pubmed: 23530767
Turk J Gastroenterol. 2010 Sep;21(3):212-7
pubmed: 20931422
Aliment Pharmacol Ther. 2001 Feb;15(2):163-9
pubmed: 11148433
Therap Adv Gastroenterol. 2014 Jan;7(1):4-13
pubmed: 24381643
Aliment Pharmacol Ther. 2005 May 15;21(10):1263-72
pubmed: 15882248
Gut. 2016 Nov;65(11):1906-1915
pubmed: 27531828
PLoS One. 2016 Oct 10;11(10):e0163743
pubmed: 27723762
Benef Microbes. 2016 Sep;7(4):519-27
pubmed: 27241906
Eur J Nutr. 2011 Feb;50(1):1-17
pubmed: 21229254
World J Gastrointest Pathophysiol. 2014 Nov 15;5(4):384-91
pubmed: 25400981
Digestion. 2001;63(1):1-7
pubmed: 11173893
Asian Pac J Cancer Prev. 2015;16(12):4885-90
pubmed: 26163609
Future Microbiol. 2016;11(3):467-75
pubmed: 26780116
Aliment Pharmacol Ther. 2001 Sep;15(9):1445-52
pubmed: 11552917
Ann Pharmacother. 2011 Jul;45(7-8):960-6
pubmed: 21693698
BMC Microbiol. 2016 Oct 18;16(1):242
pubmed: 27756217
Medicine (Baltimore). 2015 May;94(17):e685
pubmed: 25929897
Infect Drug Resist. 2016 Dec 07;9:275-289
pubmed: 27994474
Appl Environ Microbiol. 2013 Aug;79(16):4887-94
pubmed: 23770906
Asian Pac J Cancer Prev. ;18(10):2839-2843
pubmed: 29072432
J Gastroenterol Hepatol. 2012 May;27(5):851-3
pubmed: 22515805
Clin Res Hepatol Gastroenterol. 2017 Sep;41(4):466-475
pubmed: 28552432
J Gastroenterol Hepatol. 2012 May;27(5):888-92
pubmed: 22098133
Exp Ther Med. 2015 Mar;9(3):707-716
pubmed: 25667617
Sci Rep. 2016 Mar 21;6:23522
pubmed: 26997149
Gastroenterol Res Pract. 2018 Oct 16;2018:9379480
pubmed: 30410538
Aliment Pharmacol Ther. 2007 Jan 15;25(2):155-68
pubmed: 17229240
Braz J Microbiol. 2015 Oct-Dec;46(4):1201-6
pubmed: 26691482
Gut. 2012 May;61(5):646-64
pubmed: 22491499
Vojnosanit Pregl. 2016 Nov;73(11):1044-9
pubmed: 29328644
Nat Rev Gastroenterol Hepatol. 2014 Aug;11(8):506-14
pubmed: 24912386
Expert Rev Anti Infect Ther. 2018 Oct;16(10):733-735
pubmed: 30211621
Aliment Pharmacol Ther. 2015 Nov;42(10):1149-57
pubmed: 26365389
Middle East J Dig Dis. 2016 Jul;8(3):179-188
pubmed: 27698967
Appl Microbiol Biotechnol. 2018 Jan;102(1):1-7
pubmed: 29075827
Pak J Pharm Sci. 2015 May;28(3 Suppl):1087-90
pubmed: 26051728
Helicobacter. 2007 Aug;12(4):309-16
pubmed: 17669103
Gastroenterol Res Pract. 2015;2015:518018
pubmed: 26167176
PLoS One. 2013 Oct 03;8(10):e76654
pubmed: 24098547
Expert Rev Anti Infect Ther. 2012 Apr;10(4):407-9
pubmed: 22512748